Ocular inflammation is one of the most common symptom of eye disorders and diseases. The therapeutic management of this inflammation must be rapid and effective in order to avoid deleterious effects for the eye and the vision. Steroidal (SAID) and non-steroidal (NSAID) anti-inflammatory drugs and immunosuppressive agents have been shown to be effective in treating inflammation of the ocular surface of the eye by topical administration. However, it is well established that the anatomical and physiological ocular barriers are limiting factors for drug penetration. In addition, such drugs are generally characterized by a very low aqueous solubility, resulting in low bioavailability as only 1% to 5% of the applied drug permeates the cornea. The present review gives an updated insight on the conventional formulations used in the treatment of ocular inflammation, i.e., ointments, eye drops, solutions, suspensions, gels, and emulsions, based on the commercial products available on the US, European, and French markets. Additionally, sophisticated formulations and innovative ocular drug delivery systems will be discussed. Promising results are presented with micro- and nanoparticulated systems, or combined strategies with polymers and colloidal systems, which offer a synergy in bioavailability and sustained release. Finally, different tools allowing the physical characterization of all these delivery systems, as well as in vitro, ex vivo, and in vivo evaluations, will be considered with regards to the safety, the tolerance, and the efficiency of the drug products.

Dermatoses are essentially caused by infection or free radical aggression, immunoallergic disorders, or can be secondary to general diseases. Management of dermatoses by modern medicine is complex and costly, and the development of alternative treatments is urgent. Opilia amentacea Roxb. is a woody climber plant traditionally used in Burkina Faso for treatment of bad skin diseases. This study was carried out to evaluate the antimicrobial and antioxidant activities of extracts of O. amentacea and to characterize potent fractions. The antimicrobial activity was determined using the disc diffusion and microdilution methods, while antioxidant activity was assessed using the 2,2′-diphenyl-1-picrylhydrazyl radical (DPPH), 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) diammonium salt (ABTS) and ferric reducing antioxidant power (FRAP) assays. The content of the plant extracts in polyphenols and flavonoids was also studied. The results revealed several secondary metabolites in the leaves, stems and root bark extracts of the plant, including sterols, triterpenes, and flavonoids and tannins, and a generally high total polyphenol and total flavonoid content. Dichloromethane fractions of leaves (FDFe) and stem barks (FDET) exhibited the best antioxidant activity and were the most active on Gram-positive bacilli. Hexane leaves (FHFe) and hexane root bark (FHER) fractions exhibited the best antifungal activity against Candida tropicalis. High correlation (R² = 0.932) was found between the total flavonoid content of extracts and ferric-reducing antioxidant power. In view of these results, the present study describes O. amentacea as a potential source of antibacterial, antifungal and antioxidant agents and justifies the traditional uses of the plant as an anti-dermatosis plant.

The practice of voluntary depigmentation is still prevalent in Africa, with a wide range of lightening cosmetics used. Our objective was to research and quantify three regulated and/or prohibited depigmenting ingredients present in lightening cosmetics sold in Ouagadougou. Twenty-nine lightening cosmetic samples were collected from vendors and HPLC analysis was subsequently conducted to identify and measure the concentrations of hydroquinone, clobetasol propionate, and kojic acid. The presence of hydroquinone was indicated on the label of 13.79% of the products, while 51.72% contained it after analysis. Furthermore, none of the products mentioned a concentration of hydroquinone exceeding 2.00%, even though 27.58% of them contained high concentrations. For clobetasol propionate, its presence was stated on the labels of 13.79% of the products, while 31.03% contained it. One sample had a clobetasol content exceeding 0.05%, although none mentioned a concentration higher than this value. Finally, while 24.13% of the samples claimed to contain kojic acid, only 17.24% did. We also observed that 41.38% of the samples contained combinations of two depigmenting ingredients investigated, with a predominance of the hydroquinone + clobetasol propionate (27.38%). These results demonstrate that manufacturers’ declarations regarding the compositions of active ingredients in lightening cosmetics can sometimes be deceptive.

The practice of voluntary depigmentation is still prevalent in Africa, with a wide range of lightening cosmetics used. Our objective was to research and quantify three regulated and/or prohibited depigmenting ingredients present in lightening cosmetics sold in Ouagadougou. Twenty-nine lightening cosmetic samples were collected from vendors and HPLC analysis was subsequently conducted to identify and measure the concentrations of hydroquinone, clobetasol propionate, and kojic acid. The presence of hydroquinone was indicated on the label of 13.79% of the products, while 51.72% contained it after analysis. Furthermore, none of the products mentioned a concentration of hydroquinone exceeding 2.00%, even though 27.58% of them contained high concentrations. For clobetasol propionate, its presence was stated on the labels of 13.79% of the products, while 31.03% contained it. One sample had a clobetasol content exceeding 0.05%, although none mentioned a concentration higher than this value. Finally, while 24.13% of the samples claimed to contain kojic acid, only 17.24% did. We also observed that 41.38% of the samples contained combinations of two depigmenting ingredients investigated, with a predominance of the hydroquinone + clobetasol propionate (27.38%). These results demonstrate that manufacturers' declarations regarding the compositions of active ingredients in lightening cosmetics can sometimes be deceptive.

In a previous study, we reported the evaluation of the physicochemical quality and in vitro bioequivalence of different brands of amoxicillin capsules 500 mg marketed in Burkina Faso. As our goal was to document the quality and biopharmaceutical performance of essential antibiotics marketed in resource-limited countries, we investigated here, the interchangeability with the originator of five brands of amoxicillin + clavulanic acid (500mg+62.5mg) tablets distributed in Burkina Faso. The physicochemical quality of the different brands was first verified according to the USP monograph. The comparative evaluation of the in vitro dissolution profiles was performed in three different pH environments (1.2 - 4.5 - 6.8) using statistical calculations of the difference (f1) and similarity (f2) factors. All brands of amoxicillin + clavulanic acid (500mg+62.5mg) tablets, including the originator, met USP specifications for weight uniformity, identification, content and dissolution of active ingredients. However, the similarity and difference factor values showed that two generic brands (B and E) did not have similar amoxicillin dissolution profiles to the comparator product in pH 4.5 media (f1 = 23,54 and 17.02; f2=35.96 and 46.90, respectively). Therefore, these two products cannot be used interchangeably with the originator. The other three generic brands were similar to the originator and can therefore probably be used interchangeably